Kereiakes DJ - Search Results

1

A guide to drug use during percutaneous coronary intervention.

Choo JK, Young JJ, Kereiakes DJ. Choo JK, et al. Among authors: kereiakes dj. Drugs. 2002;62(18):2589-601. doi: 10.2165/00003495-200262180-00003. Drugs. 2002. PMID: 12465999 Review.

2

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Kereiakes DJ, et al. J Am Coll Cardiol. 1996 Mar 1;27(3):536-42. doi: 10.1016/0735-1097(95)00500-5. J Am Coll Cardiol. 1996. PMID: 8606262 Free article. Clinical Trial.

3

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.

Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Kereiakes DJ, et al. Circulation. 1996 Sep 1;94(5):906-10. doi: 10.1161/01.cir.94.5.906. Circulation. 1996. PMID: 8790024 Clinical Trial.

4

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.

Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Kereiakes DJ, et al. Circulation. 1997 Aug 19;96(4):1117-21. doi: 10.1161/01.cir.96.4.1117. Circulation. 1997. PMID: 9286938 Clinical Trial.

5

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention.

Kereiakes DJ, Broderick TM, Whang DD, Anderson L, Fye D. Kereiakes DJ, et al. Am J Cardiol. 1997 Sep 1;80(5):633-4. doi: 10.1016/s0002-9149(97)00437-2. Am J Cardiol. 1997. PMID: 9294997

6

Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.

Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ. Kereiakes DJ, et al. Circulation. 1998 Mar 10;97(9):857-64. doi: 10.1161/01.cir.97.9.857. Circulation. 1998. PMID: 9521334 Clinical Trial.

7

Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state.

Kereiakes DJ. Kereiakes DJ. Am J Cardiol. 1998 Apr 9;81(7A):49E-54E. doi: 10.1016/s0002-9149(98)00198-2. Am J Cardiol. 1998. PMID: 9551595 Review.

8

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.

Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ. Kereiakes DJ, et al. Circulation. 1998 Sep 29;98(13):1268-78. doi: 10.1161/01.cir.98.13.1268. Circulation. 1998. PMID: 9751674 Clinical Trial.

9

Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention.

Bhatt DL, Lincoff AM, Kereiakes DJ, Tcheng JE, Simoons ML, van der Wieken LR, Godfrey N, Califf RM, Topol EJ. Bhatt DL, et al. Among authors: kereiakes dj. Am J Cardiol. 1998 Nov 1;82(9):1105-6, A6. doi: 10.1016/s0002-9149(98)00565-7. Am J Cardiol. 1998. PMID: 9817488

10

Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?

Kereiakes DJ. Kereiakes DJ. Am Heart J. 1999 Jul;138(1 Pt 2):S39-46. doi: 10.1053/hj.1999.v138.99080. Am Heart J. 1999. PMID: 10385790 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

602 results

Search Page

Filters